Amikacin once-daily in febrile neutropenic children;AMIKACINA EN DOSIS UNICA DIARIA EN NINOS NEUTROPENICOS CON FIEBRE

Revista de Investigacion Clinica

Volumn 48, Issue 1, 1996, Pages 13-18

  Solórzano Santos, Fortino ^a   Miranda Novales, María Guadalupe ^a   Díaz Peña, Rafael ^a   Bernaldez Ríos, Roberto ^a   Díaz Bensussen, Silvia ^a   Rivera Márquez, Hugo ^a   Díaz Ponce, Humberto ^a  

^a HOSPITAL DE PEDIATRÍA   (Mexico)

Author keywords

amikacin once daily; neutropenia and fever

Indexed keywords

AMIKACIN; CARBENICILLIN;

ARTICLE; CANCER; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; FEVER; HUMAN; MALE; NEUTROPENIA; RANDOMIZED CONTROLLED TRIAL;

EID: 84865671864     PISSN: 00348376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Pizzo PA, Rubin M, Frelted A, Walsh TJ. The child with cancer and infection. I-II. Empiric therapy for fever and neutropenia and preventive strategies. J Pediatr 1991; 119:679-94.
2. Muscato JJ, Wilbur DW, Scout JJ, Fahrlender RA. An evaluation of the susceptibility patterns of gram-negative organisms isolated in cancer centers with aminoglycoside usage. J Antimicrob Chemother 1991; 27(suppl C) :1-7.
3. EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 1987; 317:1692-8.
4. Kafetzis DA, Sianidou L, Vlachos E, Davros J, Bairamis T, Papandreou Y, et al. Clinical and pharmacokinetic study of a single daily dose of amikacin in paediatric patients with severe gram-negative infections. J Antimicrob Chemother 1991; 27(Suppl C) 105-12.
5. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993; 119:584-93.
6. Viscoli C, Dubley M, Ferrea G, Boni L, Castagnola E, Barreta MA, et al. Serum concentrations and safety of single daily dosing of amikacin in children undergoing bone marrow transplantation. J Antimicrob Chemother 1991; 27(suppl C): 113-20.
7. Gilbert DN. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother 1991; 35:399-405.
8. Dudley MN, Zinner SH. Single daily dosing of amikacin in an in-vitro model. J Antimicrob Chemother 1991; 27(suppl C): 15-9.
9. Craig WA, Vogelman BS. The postantibiotic effect. Ann Intern Med 1987; 106:900-2.
10. Craig WA, Remington J, Eberts SC. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J Antimicrob Chemother 1991; 27(Suppl C): 29-40.
11. Beucaire G, Leroy O, Beuscart C, Karp P, Chidiac Ch, Caillaux M and the study group. Clinical and bacteriological efficacy, and practical aspects of amikacin given once daily for severe infections. J Antimicrob Chemother 1991; 27(suppl C): 91-103.
12. Giamarellou H, Yiallororos K, Pretrikkos G, Moscovakis E, Vavouraki E, Voutsinas D, et al. Comparative kinetics and efficacy of amikacin administered once or twice daily in the treatment of systemic gram-negative infections. J Antimicrob Chemother 1991; 27(suppl C): 73-9.
13. Meunier F, Van der Auwera P, Aoun M, Ibrahim S, Tulkens PM. Empirical antimicrobial therapy with a single daily-dose of ceftriaxone plus amikacin in febrile granulocytopenic patients: a pilot study. J Antimicrob Chemother 1991; 27(suppl C): 129-39.
14. Bouffet E, Furhmann C, Frappaz D, Couillioud D, Artiges V, Charra C, et al. Once daily antibiotic regimen in paediatric oncology. Arch Dis Child 1994; 70:484-7.
15. Washington II JA. Blood cultures. Principles and techniques. Mayo Clin Proc 1975; 50:91-7.
16. Lake DE. Amikacin/kanamicin. Therapeutic use and serum concentration monitoring. En: Taylor WO, Finn A. Individualizing drug therapy; practical application of drug monitoring. Vol 1. New York: Gross Towsend, 1981:67-111.
17. Murray RL. Creatinine. En: Pesce JA, Kaplan LA. Methods in clinical chemistry. St Louis MO: CV Mosby 1987:2-17.
18. Winston DJ, Ho HG, Bruckner DA, Champlin RE. Beta-lactam antibiotic therapy in febrile granulocitic patient. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med 1991; 115:849-59.
19. Johansson PJ, Sterby E, Ursing B. Septicemia in granulocytopenic patients: a shift in bacterial etiology. Scand J Infect Dis 1992; 24:357-60.
20. Solórzano SF, Miranda NMG, Leanos MB, Fajardo GA, Díaz PH. Factores de riesgo para sepsis en pacientes pediátricos con infección por Staphylococcus coagulasa negativa. Bol Med Hosp Infant Mex 1994; 51:384-8.
21. Tulkens PM. Pharmacokinetic and toxicological evaluation of once daily regimen versus conventional schedules of netilmicin and amikacin. J Antimicrobial Chemother 1991; 27(suppl C): 49-61.
22. Maller R, Birtt-Marie E, Isaksson B, Nilsson L. Amikacin once daily: a new dosing regimen based on drug pharmacokinetics. Scand J Infect Dis 1990; 22:575-9.
23. Cohen JJ, Harrington JT, Kassierer JP, Madias NE. Aminoglycoside nephrotoxicity. Kidney Int 1988; 33:900-11.
24. Sande M, Mandell GL. Los aminoglucósidos. En: Goodman & Gilman. Las bases farmacológicas de la terapéutica. 8a ed. México: Ed Panamericana, 1991:1065-82.
25. Sabra R, Branch RA. Role of sodium in protection by extended-spectrum penicillins against tobramycin induced nephrotoxicity. Antimicrob Agents Chemother 1990; 34:1020-5.